Keshu Zhou
0000-0001-5467-1377
Henan Cancer Hospital
11 papers found
Refreshing results…
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway
Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l -asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia
Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia
Aberrant histone modification in CD19<sup>+</sup> B cells of the patients with chronic lymphocytic leukemia
Missing publications? Search for publications with a matching author name.